Read more about the article Gilead Sciences a Top Socially Responsible Dividend Stock With 2.9% Yield (GILD)
Gilead Sciences a Top Socially Responsible Dividend Stock With 2.9% Yield (GILD)

Gilead Sciences a Top Socially Responsible Dividend Stock With 2.9% Yield (GILD)

Gilead Sciences Inc (Symbol: GILD) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.9% yield, as…

Continue ReadingGilead Sciences a Top Socially Responsible Dividend Stock With 2.9% Yield (GILD)
Read more about the article Science Applications International Corporation Reports 2% Revenue Growth in First Quarter Fiscal 2026
Science Applications International Corporation Reports 2% Revenue Growth in First Quarter Fiscal 2026

Science Applications International Corporation Reports 2% Revenue Growth in First Quarter Fiscal 2026

SAIC reports $1.88 billion in revenues, 2% growth, and reaffirms fiscal year 2026 guidance amid evolving technology demands.Quiver AI SummaryScience Applications International Corporation (SAIC) reported a revenue of $1.88 billion…

Continue ReadingScience Applications International Corporation Reports 2% Revenue Growth in First Quarter Fiscal 2026
Read more about the article Pharvaris Reports Promising Durability Data for Deucrictibant in Treating Hereditary Angioedema and Highlights Potential for Expanded Use in Bradykinin-Mediated Angioedema
Pharvaris Reports Promising Durability Data for Deucrictibant in Treating Hereditary Angioedema and Highlights Potential for Expanded Use in Bradykinin-Mediated Angioedema

Pharvaris Reports Promising Durability Data for Deucrictibant in Treating Hereditary Angioedema and Highlights Potential for Expanded Use in Bradykinin-Mediated Angioedema

Pharvaris announces positive deucrictibant data indicating safety and efficacy for hereditary angioedema treatment and potential expansion.Quiver AI SummaryPharvaris has announced promising data regarding deucrictibant, a novel oral bradykinin B2 receptor…

Continue ReadingPharvaris Reports Promising Durability Data for Deucrictibant in Treating Hereditary Angioedema and Highlights Potential for Expanded Use in Bradykinin-Mediated Angioedema
Read more about the article Castellum, Inc. CEO Glen Ives to Present at 2025 Virtual Tech Conference Hosted by Maxim Group LLC
Castellum, Inc. CEO Glen Ives to Present at 2025 Virtual Tech Conference Hosted by Maxim Group LLC

Castellum, Inc. CEO Glen Ives to Present at 2025 Virtual Tech Conference Hosted by Maxim Group LLC

Castellum, Inc. CEO Glen Ives will present at the 2025 Virtual Tech Conference from June 3rd to 5th.Quiver AI SummaryCastellum, Inc. announced that CEO Glen Ives will present at the…

Continue ReadingCastellum, Inc. CEO Glen Ives to Present at 2025 Virtual Tech Conference Hosted by Maxim Group LLC
Read more about the article Brazil Potash Corp. Reports Significant Progress and Strategic Achievements Ahead of Wells Fargo Industrials Conference
Brazil Potash Corp. Reports Significant Progress and Strategic Achievements Ahead of Wells Fargo Industrials Conference

Brazil Potash Corp. Reports Significant Progress and Strategic Achievements Ahead of Wells Fargo Industrials Conference

Brazil Potash reports key achievements in governance, construction, and financing for its Autazes Potash Project ahead of June conference.Quiver AI SummaryBrazil Potash Corp. has made significant progress in 2025 toward…

Continue ReadingBrazil Potash Corp. Reports Significant Progress and Strategic Achievements Ahead of Wells Fargo Industrials Conference
Read more about the article BioNTech and Bristol Myers Squibb Announce Global Co-Development of BNT327, a Novel Bispecific Antibody for Solid Tumors
BioNTech and Bristol Myers Squibb Announce Global Co-Development of BNT327, a Novel Bispecific Antibody for Solid Tumors

BioNTech and Bristol Myers Squibb Announce Global Co-Development of BNT327, a Novel Bispecific Antibody for Solid Tumors

BioNTech and Bristol Myers Squibb announced a collaboration to co-develop the bispecific antibody BNT327 for solid tumors.Quiver AI SummaryBioNTech and Bristol Myers Squibb have announced a partnership for the global…

Continue ReadingBioNTech and Bristol Myers Squibb Announce Global Co-Development of BNT327, a Novel Bispecific Antibody for Solid Tumors

End of content

No more pages to load